ALLAN THORNTON is a radiation oncology physician in Hampton, VA with an NPI enumerated since 2005-12-22 (≈21 years), indicating long-standing Medicare participation and operational tenure in this specialty. The provider's lifetime Medicare revenue is $3.3M and there is no Medicaid billing on file, making this effectively a single-payer (Medicare) billing profile for available data. The top three Medicare codes by revenue account for 83.5% of total Medicare revenue, indicating a highly concentrated revenue base driven by a small set of proton and imaging-related radiation therapy services. Proton therapy technical components 77522 and 77525 are the dominant service lines, generating $1.4M (42.3%) and $1.2M (34.9%) respectively; this code mix implies the provider operates with a strong focus on proton-based external beam radiation services and likely on the technical infrastructure required for those treatments. The provider ranks highly for certain proton and imaging codes: 77525 ranks #2 of 27 providers nationally and is described as notably above typical national volume (96th percentile), while 77522 ranks #2 of 4 providers nationally at the 67th percentile, suggesting above-typical to high national presence for proton therapy services relative to peers. Several support and planning codes are also reported at unusually high volumes: G6002 is an extreme outlier (rank #4 of 2280 providers, 100th percentile) with 3.6K claims and $210.1K revenue, and 77334 is an extreme outlier (rank #24 of 4463 providers, 99th percentile) with 651 claims and $63.8K revenue, indicating unusually high use of stereoscopic x-ray guidance and custom device design services for radiation delivery. Other planning, simulation, and physics services (e.g., 77427, 77336, 77295, 77280) appear notably above typical national volume or high percentile ranks, which supports a practice profile that handles complex planning, quality assurance, and ongoing physics consultation alongside its primary proton therapy treatments. The absence of any Medicaid billing means comparisons to in-state Medicaid peers are not possible; as a result, competitive standing and payer-mix conclusions should be interpreted strictly within the Medicare context and not extrapolated to the broader commercial or Medicaid markets.